Flu-Bu-Mel Conditioning Regimen for Myeloid Disease

  • STATUS
    Recruiting
  • End date
    Dec 15, 2023
  • participants needed
    24
  • sponsor
    Shanghai Jiao Tong University School of Medicine
Updated on 26 January 2021

Summary

For patients with acute myeloid leukemia (AML) or myelodyspasia syndrome undergoing allo-HSCT, the conditioning regimen will be 5-day Fludarabine, 2-day Busulifan and 2-day melphalan

Description

For patients with acute myeloid leukemia (AML) or myelodyspasia syndrome undergoing allo-HSCT, the conditioning regimen will be Fludarabine (30mg/m2, d-7 to d-3) + Busulifan 3.2mg/kg (d-7 to d-6) + melphalan 70mg/m2 (d-4 and d-3). The GVHD prophylaxis will be PT-CY (Cyclophosphamide 50mg/kg d+3 and d+4) + low-dose ATG (2.5mg/kg) on d+15.

Details
Condition Relapse Rate After Allo-HSCT, Relapse Rate After Allo-HSCT, Relapse Rate After Allo-HSCT, Relapse Rate After Allo-HSCT, Relapse Rate After Allo-HSCT
Treatment Flu-Bu-Mel
Clinical Study IdentifierNCT04269811
SponsorShanghai Jiao Tong University School of Medicine
Last Modified on26 January 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Is your age between 16 yrs and 65 yrs?
Gender: Male or Female
Do you have Relapse Rate After Allo-HSCT?
Do you have any of these conditions: Do you have Relapse Rate After Allo-HSCT??
acute myeloid leukemia (CR1 or CR2) or myelodysplasia syndrome
patients with HLA matched sibling, unrelated or Haplo-identical donor

Exclusion Criteria

patients with active infection
patients with abnormal liver function damage: ALT/AST above 2X normal range
patients with abnormal renal function damage Scr>160mol/L
patients with insufficient pulmonary function (FEV1FVCDLCO<50%and heart failure or with EF <50%)
patients with mental instability or unwilling to give inform consent
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note